FoxM1表达在非小细胞肺癌中的预后意义
Prognostic significance of FoxM1 expression in non-small cell lung cancer.
作者信息
Sun Qing, Dong Min, Chen Yujuan, Zhang Jiawei, Qiao Jinpeng, Guo Xuedan
机构信息
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
出版信息
J Thorac Dis. 2016 Jun;8(6):1269-73. doi: 10.21037/jtd.2016.04.13.
BACKGROUND
Various studies examined the relationship between FoxM1 overexpression with the clinical outcome in patients with non-small cell lung cancer (NSCLC), but yielded conflicting results.
METHODS
Electronic databases updated to Jan 01, 2015 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between FoxM1 overexpression and survival of patients with NSCLC Survival data were aggregated and quantitatively analyzed.
RESULTS
We performed a meta-analysis of seven studies (n=860 patients) that evaluated the correlation between FoxM1 overexpression and survival in patients with NSCLC. Combined hazard ratios suggested that FoxM1 overexpression was associated with poor prognosis of overall survival (OS) (HR =1.73, 95% CI: 1.32-2.14) in patients with NSCLC.
CONCLUSIONS
FoxM1 overexpression indicates a poor prognosis for patients with NSCLC.
背景
多项研究探讨了非小细胞肺癌（NSCLC）患者中FoxM1过表达与临床结局之间的关系，但结果相互矛盾。
方法
检索截至2015年1月1日更新的电子数据库以查找相关研究。对符合条件的研究进行荟萃分析，这些研究定量评估了FoxM1过表达与NSCLC患者生存率之间的关系。汇总生存数据并进行定量分析。
结果
我们对7项研究（n = 860例患者）进行了荟萃分析，评估了FoxM1过表达与NSCLC患者生存率之间的相关性。合并风险比表明，FoxM1过表达与NSCLC患者总生存期（OS）预后不良相关（HR = 1.73，95%CI：1.32 - 2.14）。
结论
FoxM1过表达表明NSCLC患者预后不良。
Zotero 插件